Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression

This episode, titled 'Risk Stratification and Weight Loss as Therapy: A Hepatologist's Framework for Managing MASH Progression,' features Nadege Gunn, MD discussing the following critical questions:

1. How do you risk-stratify your patients, and what clinical or metabolic factors most reliably predict progression?
2. What does the literature tell us about the relationship between meaningful weight loss and fibrosis regression, and how does that inform your thinking about weight-loss therapy as a hepatic intervention?

Gunn outlined her clinical framework for risk stratifying MASH patients, identifying type 2 diabetes as the single most compelling risk factor, followed by the broader constellation of metabolic comorbidities, all of which drive her index of suspicion for at-risk fibrosis and inform her decision to implement more advanced diagnostic tools at the point of specialist care, including elastography and MR-based technologies that quantify both fat and fibrosis to guide treatment decisions. She also described how the results of these advanced assessments directly shape her clinical approach, determining whether to initiate available MASH-directed therapies, maintain close surveillance for patients at risk of hepatic decompensation or liver cancer, or pursue additional workup, reinforcing that risk stratification is not a one-time event but an ongoing, dynamic process tied to the patient's evolving metabolic and hepatic status. Gunn further emphasized that weight management is the cornerstone of MASH care, citing evidence showing that as little as 3 to 5% body weight reduction begins to reduce fat in the liver, while achieving 10% weight loss can meaningfully improve MASH itself and drive fibrosis regression, making weight-directed therapy an indispensable component of any comprehensive MASH management strategy alongside emerging liver-directed pharmacotherapies.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Beyond GLP-1: The Biological Case for Dual Incretin Therapy in MASH,' Nadege Gunn will continue her discussion on obesity and MASH and highlight the biological rationale for combining GLP-1 and glucagon receptor agonism as a potentially more liver-targeted therapeutic approach.